| name | Tigecycline |
| classification | Tetracycline derivative, Glycylcycline antibiotic |
| pharmacokinetics | Tigecycline is rapidly absorbed after oral administration, achieving peak plasma concentrations within 2-4 hours. It is highly protein-bound (approximately 90%) and distributed throughout various tissues and organs, including the lungs, kidneys, and bones. Elimination is primarily through hepatic metabolism, with a terminal half-life of approximately 10-11 hours. Renal excretion is minimal, making tigecycline a good choice for patients with renal impairment. |
| suggested dosage | The recommended dosage of tigecycline varies depending on the infection and the patient's condition. For adults, the usual dose is 100 mg intravenously or orally every 12 hours. Consult with a healthcare professional for specific dosage recommendations tailored to the individual patient. |
| indications | Tigecycline is indicated for the treatment of serious bacterial infections, particularly those caused by Gram-negative bacteria, including atypical bacteria. This includes infections of the skin and soft tissues, respiratory tract, urinary tract, and intra-abdominal infections. It is also used for infections in individuals with comorbidities or those who have not responded to other antibiotics. Important Note: The decision to use tigecycline should be made by a healthcare professional after considering the potential benefits and risks. |
| safety in pregnancy | Limited data exist on the use of tigecycline during pregnancy. While the drug does cross the placental barrier, the safety profile in pregnant women is not fully understood. It is recommended that tigecycline be used in pregnancy only when the potential benefits outweigh the potential risks. Consult with an obstetrician/gynecologist. |
| safety in breastfeeding | There is limited data available on tigecycline's excretion in breast milk. Therefore, tigecycline should be used with caution during breastfeeding, particularly in nursing mothers with serious or life-threatening infections. The risk to the infant should be carefully evaluated against the benefits of tigecycline treatment to the mother. Consult with a lactation consultant and a healthcare professional. |
| side effects | | 1 | Nausea | | 2 | Vomiting | | 3 | Diarrhea | | 4 | Headache | | 5 | Abdominal pain | | 6 | Elevated liver enzymes | | 7 | Infusion-related reactions (when administered intravenously) | | 8 | Skin rash | | 9 | Pruritus (itching) | | 10 | Superinfection (a secondary infection) |
|
| alternatives | |
| contraindications | Known hypersensitivity to tigecycline or any component of the formulation. |
| interactions | Tigecycline can interact with other medications. It is essential to inform your doctor about all medications you are taking, including over-the-counter drugs, supplements, and herbal remedies. Possible interactions include those involving CYP3A4 enzymes and/or other drugs affecting renal function. |
| warnings and precautions | | 1 | Monitor liver function tests during treatment | | 2 | Close monitoring for signs of superinfection (oral candidiasis) | | 3 | Patients with pre-existing liver or kidney disease may require dosage adjustments. Consult with a healthcare professional. | | 4 | Avoid exposure to sunlight; use sunscreen |
|
| additional informations | Tigecycline should be stored in a cool, dry place, protected from light. |
| patient specific details | |
